Intellipharmaceutics International Inc. (IPCIF)
Market Cap | 5.62M |
Revenue (ttm) | 3.48M |
Net Income (ttm) | -8.08M |
Shares Out | 21.58M |
EPS (ttm) | -0.13 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | March 2 |
Last Price | $0.2945 |
Previous Close | $0.2900 |
Change ($) | 0.0045 |
Change (%) | 1.55% |
Day's Open | 0.3000 |
Day's Range | 0.2945 - 0.3000 |
Day's Volume | 7,060 |
52-Week Range | 0.0588 - 0.48 |
News
TORONTO, ON / ACCESSWIRE / March 1, 2021 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
TORONTO, ON / ACCESSWIRE / December 23, 2020 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing...
About IPCIF
Intellipharmaceutics International, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hype... [Read more...]
Industry Biotechnology | Founded 1998 |
CEO Isa Odidi | Country Canada |
Stock Exchange OTCMKTS | Ticker Symbol IPCIF |
Financial Performance
In 2019, IPCIF's revenue was $3.48 million, an increase of 103.21% compared to the previous year's $1.71 million. Losses were -$8.08 million, -41.19% less than in 2018.